NCT03944954 - Neural Mechanisms of Cannabinoid-impaired Decision-Making in Emerging Adults | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2017

Primary Completion Date

December 13, 2023

Study Completion Date

December 13, 2023

Conditions

NeurosciencesSubstance-Related DisordersBehavior Problem

Interventions

DEVICE

Placebo TMS Sham

Individuals will receive placebo dose and sham TMS.

DRUG

Marinol 10Mg Capsule TMS Sham

Individuals will receive 10mg dose and sham TMS.

DRUG

Marinol 30Mg Capsule TMS Sham

Individuals will receive 30mg dose and sham TMS.

DEVICE

Placebo TMS Real

Individuals will receive placebo and real TMS.

OTHER

Marinol 10Mg Capsule TMS Real

Individuals will receive10mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

OTHER

Marinol 30Mg Capsule TMS Real

Individuals will receive 30mg THC and real TMS. Intervention type: Other (combination device/drug intervention)

Trial Locations (1)

Neurobehavioral Systems Lab of the University of Kentucky College of Medicine, Lexington

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Michael J. Wesley, PhD

OTHER